Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
BMC Public Health|June 5, 2024
Social contact and the perceived impact of social distancing on health outcomes during the COVID-19 pandemic among community dwelling older adults taking part in the OPAL cohort studyEsther Williamson, Ioana R Marian, Paul Newell, et al.
European Journal of Clinical Pharmacology|December 15, 2019
Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumoniaShampa Das, Diansong Zhou, Wright W Nichols, et al.
Journal of Physiotherapy|June 21, 2025
Exploring the mediators of the BOOST intervention on walking disability at 12 months: a causal mediation analysisLianne Wood, Christine Comer, Paul Newell, et al.
Drug Safety|July 1, 2020
Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial ProgrammeKaren Cheng, Paul Newell, Joseph W Chow, et al.
The Lancet. Infectious Diseases|April 25, 2016
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 studyYehuda Carmeli, Jon Armstrong, Peter J Laud, et al.
Antimicrobial Agents and Chemotherapy|February 5, 2020
Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-AvibactamJianguo Li, Mark Lovern, Todd Riccobene, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2016
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial ProgramFlorian M Wagenlehner, Jack D Sobel, Paul Newell, et al.
Environment, Development and Sustainability|January 11, 2023
Perceived feasibility of sward management options in permanent grassland of Alpine regions and expected effects on delivery of ecosystem servicesGabriele Mack, Nadja El Benni, Martina Spörri, et al.
The Journal of Antimicrobial Chemotherapy|June 19, 2018
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programmeGregory G Stone, Paul Newell, Leanne B Gasink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2016
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 ProgramJohn E Mazuski, Leanne B Gasink, Jon Armstrong, et al.
Pageof 3